Sandoz Ltd has issued a class two recall for certain batches of Co-amoxiclav 125 mg/31.25mg/5ml and 250 mg/62.5mg/5ml powder for oral suspension.

The Medicines and Healthcare products Regulatory Agency (MHRA) said the company issued its recall as a precaution after detecting a potential packaging problem related to poor seal adherence which could cause clumping of the powder within the bottle.

“A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective,” the MHRA statement read.

Pharmacy teams are asked to quarantine all the remaining stocks of the impacted batches and return it to the original supplier.

Product information:

Batch Number Expiry Date Pack Size First Distributed
  HT6202   Feb 2021   100ml   Sep 2018
  HT7923   Feb 2021   100ml   Jul 2018

 

LEAVE A REPLY